LS

Lasa Supergenerics Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Lasa Supergenerics Q2 Results 2026: Net loss ₹2 Cr, Revenue ₹0 Cr

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹0Cr
−99.7% YoY
−99.2% QoQ
Net profit
−₹2Cr
Q2 FY26: −₹6 Cr
Margin
−900%
−769.3 pp YoY
−787 pp QoQ

Lasa Supergenerics Ltd Q2 FY27 key numbers

Revenue
Total income for the quarter: Rs. 1.55 Lakhs, versus Rs. 306.81 Lakhs in the corresponding quarter last year.

As stated in Lasa Supergenerics Ltd's Q2 FY27 results statement · published 16 Nov 2026. Reported figures, not investment advice.

Based on Lasa Supergenerics Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹4
Market cap₹20 Cr

The short version

Revenue from operations for Q2 ending Sept 30, 2026: Rs. 1.24 Lakhs, down sharply from Rs. 306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). EBITDA for Q2 FY2026: Rs. 1.8 million, down from Rs. 52.9 million in Q2 FY2025 (Year-on-Year decline of 97%).

From Lasa Supergenerics Ltd's Q2 FY27 earnings-call transcript · updated 16 Nov 2026.

How did Lasa Supergenerics' revenue grow in the September 2026 quarter?

  • Revenue from operations for Q2 ending Sept 30, 2026: Rs. 1.24 Lakhs, down sharply from Rs. 306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY).
  • Total income for the quarter: Rs. 1.55 Lakhs, versus Rs. 306.81 Lakhs in the corresponding quarter last year.
  • Operational disruptions due to a May 2025 factory fire severely impacted production and revenue; all operations halted at primary production unit and dependent units.
  • The company is exploring recovery strategies, including contract manufacturing or leasing facilities, and potential funding arrangements to restore operations.

What happened to Lasa Supergenerics' margins in Q2 FY27?

See what Lasa Supergenerics Ltd said on profitability & margins — free account, 30 seconds.

What capex is Lasa Supergenerics planning?

It primarily covers: - Fire incident impact on the existing factory (C-4 unit at Lote Parshuram Industrial Area), causing operational shutdown. - Impairment and damage assessment of tangible assets due to the fire. - Suspension of production and exploration of recovery strategies.

2 more points from Lasa Supergenerics Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Lasa Supergenerics raising money or cutting debt?

See what Lasa Supergenerics Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Lasa Supergenerics' order book?

Key highlights include: - Fire incident causing suspension of production and significant asset damage. - Financial losses and exceptional items related to the fire. - No production activities ongoing due to operational constraints. - Management's exploration of contract manufacturing or leasing options.

2 more points from Lasa Supergenerics Ltd's call on order book

Create a free account to keep reading this call

Lasa Supergenerics Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Lasa Supergenerics Ltd Q2 FY27 results — key figures

Lasa Supergenerics Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue03-99.7%1-99.2%
Operating profit (EBITDA)-0-4—-1—
Operating margin-900%-130.7%-769.3 pp-113%-787 pp
Profit before tax-2-6—-3—
Net profit (PAT)-2-6—-4—
EPS (₹)-0.37-1.25—-0.71—

Source: Lasa Supergenerics Ltd's results filing to NSE (standalone), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹0 Cr, net loss ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

  • Alpa Laboratorie (Q2 FY27)

    Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lasa Supergenerics Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lasa Supergenerics Ltd Q2 FY27 results?

Lasa Supergenerics reported a net loss of ₹2 Cr on revenue of ₹0 Cr (−99.7% YoY) in Q2 FY27.

What is Lasa Supergenerics Ltd share price analysis?

Lasa Supergenerics Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹20 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Lasa Supergenerics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.